Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Gross Margin: 2015-2025

Historic Gross Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to 100.00%.

  • Cartesian Therapeutics' Gross Margin changed negligibly% to 100.00% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.00%, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of 100.00% for FY2024, which is negligibly% changed negligibly from last year.
  • Cartesian Therapeutics' Gross Margin amounted to 100.00% in Q3 2025, which was down 0.00% from 100.00% recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Gross Margin registered a high of 100.00% during Q1 2021, and its lowest value of 100.00% during Q1 2021.
  • For the 3-year period, Cartesian Therapeutics' Gross Margin averaged around 100.00%, with its median value being 100.00% (2025).